New interim results from a six-month investigator-initiated trial (IIT) supported by Galderma, regarding the clinical sequencing of women in menopause, show the combination of Restylane Skinboosters and Sculptra drove meaningful improvements in skin barrier function, hydration and patient satisfaction, the company announced in a press release.
The results showed the most pronounced gains in hydration when using Restylane Skinboosters first, which is critical for perimenopausal skin health.
Related: Restylane Contour for Cheek Augmentation
Data from a separate IIT show the cellular composition of adipose (fat) tissue may be altered in patients experiencing aesthetic changes in the abdomen following medication-driven weight loss.
This observations offers a biological explanation for clinician‑reported volume loss beyond weight reduction alone, and underscores the importance of including regenerative aesthetic treatments as part of the patients’ weight loss journey.
“Menopause is associated with a distinct and often under-recognized set of skin changes, including dryness, barrier dysfunction, and progressive declines in skin quality," Dr. Andreas Nikolis, the study's lead investigator and a board-certified plastic surgeon from Montreal, Canada said in the press release.
"This first-of-its-kind clinical study is helping address an important unmet need by generating objective data in a population that has historically been overlooked in aesthetic research," he continued.
